Kim Sunghyun, Sung Daekyung, Chang Jeong Ho
Center for Convergence Bioceramic Materials , Korea Institute of Ceramic Engineering and Technology , Chungbuk 28160 , Republic of Korea . Email:
Medchemcomm. 2017 Nov 2;9(1):108-112. doi: 10.1039/c7md00468k. eCollection 2018 Jan 1.
In this study, we prepared protein A grafted magnetic nanoparticles for the industrial large-scale purification of antibodies with enhancement of binding capacity and immobilization by controlled orientation with chlorophenylsilane (CPTMS) on the surface. For site-specific immobilization of protein A, genetically modified protein A with a cysteine residue was expressed in and purified by affinity chromatography. To improve the surface area to volume ratio and increase the immobilization amount of protein A, chlorophenylsilane functionalized magnetic nanoparticles (CPTMS@MNPs) were prepared, which are smaller nanoparticles with an average diameter of 20 nm compared to commercial magnetic microparticles (Dynabeads) with an average size of 2.8 μm. The CPTMS@MNPs showed the enhancement of protein A immobilization and binding capacity to antibodies, being 11.5-fold and 7-fold higher than those of commercial Dynabeads, respectively. In addition, the CPTMS@MNPs retained about 80% of the initial protein binding capacity until the third stage of recycling. Therefore, protein A grafted CPTMS@MNPs may be useful for the industrial large-scale purification of antibodies.
在本研究中,我们制备了蛋白A接枝磁性纳米颗粒,用于工业大规模纯化抗体,通过在表面用氯苯基硅烷(CPTMS)进行可控取向来增强结合能力和固定化。为了实现蛋白A的位点特异性固定,在大肠杆菌中表达了带有半胱氨酸残基的基因工程化蛋白A,并通过亲和色谱法进行纯化。为了提高表面积与体积比并增加蛋白A的固定量,制备了氯苯基硅烷功能化磁性纳米颗粒(CPTMS@MNPs),与平均尺寸为2.8μm的商业磁性微球(Dynabeads)相比,其为平均直径20nm的较小纳米颗粒。CPTMS@MNPs表现出蛋白A固定化和与抗体结合能力的增强,分别比商业Dynabeads高11.5倍和7倍。此外,CPTMS@MNPs在循环的第三阶段之前保留了约80%的初始蛋白结合能力。因此,蛋白A接枝的CPTMS@MNPs可能对工业大规模纯化抗体有用。